Goals of Care: in mNSCLC Balancing QOL and Treatment Maintenance

EP: 1.Sarah’s Journey With ALK+ Metastatic NSCLC

EP: 2.Patient Education: Preparing Patients for ALK Inhibitor Treatment

EP: 3.Strategies for Managing Neurotoxic AEs With Lorlatinib

EP: 4.Lorlatinib AE Management: Weight Gain and GI Issues

EP: 5.Multidisciplinary Approach to AE Management With Lorlatinib

EP: 6.Real-World Management of AEs with ALK Inhibitors

EP: 7.Eleanor’s Journey With KRAS+ Metastatic NSCLC

EP: 8.Educating Patients About AEs Associated With KRAS-Targeted Therapies in NSCLC

EP: 9.Managing AEs Associated With Adagrasib for NSCLC

Now Viewing

EP: 10.Goals of Care: in mNSCLC Balancing QOL and Treatment Maintenance

Video content above is prompted by the following:

• Are there any serious AEs of note that worry you? Which AEs have the biggest impact on a patient’s quality of life?
• How do you balance symptom management with maintaining treatment efficacy?
• What has been your experience with the incidence and management of GI adverse events? Fatigue?
• How do these compare to AEs associated with other similar therapies.
• How do you handle dose modifications or treatment interruptions due to adverse events?
• Do you find does modifications impact patient outcomes?
• When might you consider stopping treatment
• Can you share any tips for working together as a multidisciplinary care team to ensure the most effective management of AEs associated with KRAS targeted therapies?